Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #9 on AEON Biopharma Inc (AEON)
DewDiligence
11/13/23 11:47 AM
#10 RE: DewDiligence #9
The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023. The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023.
01/18/24 6:33 PM
#11 RE: DewDiligence #9
03/19/24 4:47 PM
#13 RE: DewDiligence #9